Podocyte expression of human phospholipase A2 receptor 1 causes immune-mediated membranous nephropathy in mice

NM Tomas, S Dehde, C Meyer-Schwesinger… - Kidney international, 2023 - Elsevier
NM Tomas, S Dehde, C Meyer-Schwesinger, M Huang, I Hermans-Borgmeyer, J Maybaum…
Kidney international, 2023Elsevier
Antibody-mediated autoimmune pathologies like membranous nephropathy are difficult to
model, particularly in the absence of local target antigen expression in model organisms
such as mice and rats; as is the case for phospholipase A2 receptor 1 (PLA2R1), the major
autoantigen in membranous nephropathy. Here, we generated a transgenic mouse line
expressing the full-length human PLA2R1 in podocytes, which has no kidney impairment
after birth. Beginning from the age of three weeks, these mice spontaneously developed anti …
Antibody-mediated autoimmune pathologies like membranous nephropathy are difficult to model, particularly in the absence of local target antigen expression in model organisms such as mice and rats; as is the case for phospholipase A2 receptor 1 (PLA2R1), the major autoantigen in membranous nephropathy. Here, we generated a transgenic mouse line expressing the full-length human PLA2R1 in podocytes, which has no kidney impairment after birth. Beginning from the age of three weeks, these mice spontaneously developed anti-human PLA2R1 antibodies, a nephrotic syndrome with progressive albuminuria and hyperlipidemia, and the typical morphological signs of membranous nephropathy with granular glomerular deposition of murine IgG in immunofluorescence and subepithelial electron-dense deposits by electron microscopy. Importantly, human PLA2R1-expressing Rag2–/– mice, which lack mature and functioning B and T lymphocytes, developed neither anti-PLA2R1 antibodies nor proteinuria. Thus, our work demonstrates that podocyte expression of human PLA2R1 can induce membranous nephropathy with an underlying antibody-mediated pathogenesis in mice. Importantly, this antibody-mediated model enables proof-of-concept evaluations of antigen-specific treatment strategies, e.g., targeting autoantibodies or autoantibody-producing cells, and may further help understand the autoimmune pathogenesis of membranous nephropathy.
Elsevier